EP1581052B1 - An emollient alcohol skin disinfecting formulation - Google Patents
An emollient alcohol skin disinfecting formulation Download PDFInfo
- Publication number
- EP1581052B1 EP1581052B1 EP04700579A EP04700579A EP1581052B1 EP 1581052 B1 EP1581052 B1 EP 1581052B1 EP 04700579 A EP04700579 A EP 04700579A EP 04700579 A EP04700579 A EP 04700579A EP 1581052 B1 EP1581052 B1 EP 1581052B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- log
- alcohol
- composition
- amount
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 117
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 76
- 230000000249 desinfective effect Effects 0.000 title claims abstract description 46
- 239000003974 emollient agent Substances 0.000 title claims abstract description 22
- 238000009472 formulation Methods 0.000 title abstract description 73
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 29
- 239000003755 preservative agent Substances 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000004599 antimicrobial Substances 0.000 claims abstract description 17
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 17
- 239000004909 Moisturizer Substances 0.000 claims abstract description 16
- 230000001333 moisturizer Effects 0.000 claims abstract description 16
- 230000002335 preservative effect Effects 0.000 claims abstract description 15
- 125000002091 cationic group Chemical group 0.000 claims abstract description 8
- 235000019441 ethanol Nutrition 0.000 claims description 53
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 27
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 20
- 239000002562 thickening agent Substances 0.000 claims description 19
- 229960003333 chlorhexidine gluconate Drugs 0.000 claims description 18
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 claims description 18
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 12
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 12
- 235000011187 glycerol Nutrition 0.000 claims description 10
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 8
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 8
- 229960001950 benzethonium chloride Drugs 0.000 claims description 7
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims description 7
- 239000002480 mineral oil Substances 0.000 claims description 7
- 239000000758 substrate Substances 0.000 claims description 7
- 229940081733 cetearyl alcohol Drugs 0.000 claims description 6
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 6
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 6
- 229960002216 methylparaben Drugs 0.000 claims description 6
- 235000010446 mineral oil Nutrition 0.000 claims description 6
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 6
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 6
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 6
- 229960003415 propylparaben Drugs 0.000 claims description 6
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 claims description 5
- 125000002511 behenyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 5
- DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 claims description 4
- DNKGZSOYWMQDTK-UHFFFAOYSA-N 3-iodoprop-1-ynyl N-butylcarbamate Chemical compound CCCCNC(=O)OC#CCI DNKGZSOYWMQDTK-UHFFFAOYSA-N 0.000 claims description 4
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 claims description 4
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 claims description 4
- 229960001083 diazolidinylurea Drugs 0.000 claims description 4
- 229940008099 dimethicone Drugs 0.000 claims description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 4
- 229960004867 hexetidine Drugs 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 4
- 229960004063 propylene glycol Drugs 0.000 claims description 4
- 229940032094 squalane Drugs 0.000 claims description 4
- 229960003500 triclosan Drugs 0.000 claims description 4
- QLAJNZSPVITUCQ-UHFFFAOYSA-N 1,3,2-dioxathietane 2,2-dioxide Chemical compound O=S1(=O)OCO1 QLAJNZSPVITUCQ-UHFFFAOYSA-N 0.000 claims description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 3
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000004264 Petrolatum Substances 0.000 claims description 3
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 claims description 3
- 229960003260 chlorhexidine Drugs 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 229940066842 petrolatum Drugs 0.000 claims description 3
- 235000019271 petrolatum Nutrition 0.000 claims description 3
- 229960005323 phenoxyethanol Drugs 0.000 claims description 3
- 229940057981 stearalkonium chloride Drugs 0.000 claims description 3
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 235000013772 propylene glycol Nutrition 0.000 claims description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 8
- 229920002678 cellulose Polymers 0.000 abstract description 4
- 239000001913 cellulose Substances 0.000 abstract description 4
- 229920000642 polymer Polymers 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 29
- 239000000243 solution Substances 0.000 description 26
- 230000009467 reduction Effects 0.000 description 22
- 206010015150 Erythema Diseases 0.000 description 12
- 206010070834 Sensitisation Diseases 0.000 description 12
- 231100000321 erythema Toxicity 0.000 description 12
- 230000008313 sensitization Effects 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 10
- 244000005700 microbiome Species 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 206010030113 Oedema Diseases 0.000 description 9
- XIWFQDBQMCDYJT-UHFFFAOYSA-M benzyl-dimethyl-tridecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 XIWFQDBQMCDYJT-UHFFFAOYSA-M 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000000813 microbial effect Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 230000007794 irritation Effects 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 229920003091 Methocel™ Polymers 0.000 description 5
- 239000003205 fragrance Substances 0.000 description 5
- 239000004166 Lanolin Substances 0.000 description 4
- -1 cationic quaternary ammonium compound Chemical class 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 4
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 4
- 229940039717 lanolin Drugs 0.000 description 4
- 235000019388 lanolin Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 241000222122 Candida albicans Species 0.000 description 3
- 241000194032 Enterococcus faecalis Species 0.000 description 3
- 241000588747 Klebsiella pneumoniae Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 241000606124 Bacteroides fragilis Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000194031 Enterococcus faecium Species 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- 241000588915 Klebsiella aerogenes Species 0.000 description 2
- 241000588749 Klebsiella oxytoca Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 150000004287 bisbiguanides Chemical class 0.000 description 2
- 229920006317 cationic polymer Polymers 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 229940031661 dimethicone 350 Drugs 0.000 description 2
- 229940092559 enterobacter aerogenes Drugs 0.000 description 2
- 229940032049 enterococcus faecalis Drugs 0.000 description 2
- 229940047650 haemophilus influenzae Drugs 0.000 description 2
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 2
- 229960004068 hexachlorophene Drugs 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000005201 scrubbing Methods 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 description 1
- QYYMDNHUJFIDDQ-UHFFFAOYSA-N 5-chloro-2-methyl-1,2-thiazol-3-one;2-methyl-1,2-thiazol-3-one Chemical compound CN1SC=CC1=O.CN1SC(Cl)=CC1=O QYYMDNHUJFIDDQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000588626 Acinetobacter baumannii Species 0.000 description 1
- 241001232615 Acinetobacter baumannii ATCC 19606 = CIP 70.34 = JCM 6841 Species 0.000 description 1
- 101100508888 Bacillus subtilis (strain 168) iolJ gene Proteins 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 241000222173 Candida parapsilosis Species 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010051814 Eschar Diseases 0.000 description 1
- 239000004605 External Lubricant Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101000666379 Homo sapiens Transcription factor Dp family member 3 Proteins 0.000 description 1
- ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000031650 Surgical Wound Infection Diseases 0.000 description 1
- 102100038129 Transcription factor Dp family member 3 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- BWNMWDJZWBEKKJ-UHFFFAOYSA-M benzyl-docosyl-dimethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 BWNMWDJZWBEKKJ-UHFFFAOYSA-M 0.000 description 1
- 238000003339 best practice Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 229940055022 candida parapsilosis Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- WDRFFJWBUDTUCA-UHFFFAOYSA-N chlorhexidine acetate Chemical compound CC(O)=O.CC(O)=O.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WDRFFJWBUDTUCA-UHFFFAOYSA-N 0.000 description 1
- 229960001884 chlorhexidine diacetate Drugs 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000036576 dermal application Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 231100000333 eschar Toxicity 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229940035535 iodophors Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000002068 microbial inoculum Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000007964 self emulsifier Substances 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 231100000933 sensitization response Toxicity 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229940043810 zinc pyrithione Drugs 0.000 description 1
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N31/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
- A01N31/02—Acyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/416—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/43—Guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/54—Polymers characterized by specific structures/properties
- A61K2800/542—Polymers characterized by specific structures/properties characterized by the charge
- A61K2800/5426—Polymers characterized by specific structures/properties characterized by the charge cationic
Definitions
- the present invention relates to an antimicrobial composition for use as an emollient alcohol based skin disinfectant that will not irritate or dry the skin.
- the skin disinfecting formulations of the present invention are particularly useful in the healthcare profession as a hand healthcare preparation or as a pre-surgical scrub without requiring a secondary emollient application.
- Hand washing by healthcare professionals is an essential component of infection control activities.
- Healthcare professionals attending to patient care wash their hands to control the spread of infection from patient to patient and surgical procedures are routinely proceeded by surgical hand scrubbing and patient pre-operative skin preparation.
- Hand washing procedures are performed in several ways. Several procedures include an ordinary antimicrobial bar soap, a skin disinfecting alcohol based preoperative preparation agent, or rubbing alcohol The repeated use of these procedures causes the hands to become rough, dry and cracked.
- the majority of the commercially available scrubs include detergents and an antimicrobial agent or a preservative.
- the antimicrobial or preservative agents include iodine formulations, iodophors, phenolic compounds such as parachlorometaxylenol and hexachlorophene and bis-biguanides such as chlorhexidine gluconate (CHG).
- CHG chlorhexidine gluconate
- WO-A-01/41567 discloses an antimicrobial composition comprising an alcohol, an effective amount of a cationic quaternary ammonium compound, phenoxy ethanol, and optionally a biguanide compound and an effective amount of a surfactant system, the system comprising surfactant other than anionic surfactants.
- US-A-6,110,908 describes an antiseptic formulation for topical application to animal skin, comprising an antimicrobial alcohol selected from the group consisting of ethanol, isopropanol, n-propanol and mixtures thereof, an antimicrobial lipid selected from the group consisting of free fatty acids having from six to eighteen carbons, glycerol monolaurate and mixtures thereof and zinc pyrithione.
- an antimicrobial alcohol selected from the group consisting of ethanol, isopropanol, n-propanol and mixtures thereof
- an antimicrobial lipid selected from the group consisting of free fatty acids having from six to eighteen carbons, glycerol monolaurate and mixtures thereof and zinc pyrithione.
- EP-A-0689767 discloses a skin disinfecting formulation for use as a skin washing agent, comprising an alcohol, a block copolymer, a foaming surfactant, an emulsifier, a cleaning agent, a polyalkylene glycol, an emollient and water which is described as providing anti microbial effectiveness to the skin.
- alcohol in general is recognized for its very effective disinfecting properties, it is not used directly with skin or in scrab formulations because it is a defatting agent. When alcohol is applied to the human skin, it makes it very dry, often developing chapped and cracked skin. Furthermore, it is difficult to formulate a detergent solution with alcohol that will lather like ordinary soaps and detergents when used with water. However, due to the disinfecting properties of alcohol, it is desirable to produce a skin disinfecting formulation with alcohol which is mild and gentle to the skin, and is effective at controlling microorganism populations on the skin.
- the present invention is a skin disinfecting formulation that provides antimicrobial effectiveness and is mild and gentle to human skin.
- the skin disinfecting formulation desirably comprises an alcohol, a thickening agent, a preservative, an emulsifier, a moisturizer and/or emollient and water.
- the skin disinfecting formulation may further comprise a colorant or a fragrance.
- the present invention provides the following:
- the skin disinfecting formulations of the present invention are useful in providing substantial antimicrobial effectiveness and surprisingly, provide substantial non-irritancy to the skin in view of the alcohol component of the formulations.
- Another attribute of the skin disinfecting formulation is its ability to not dry the skin.
- Another advantage of the skin disinfecting formulation is the compatibility with other Chlorohexidine Gluconate products, which enhances the antimicrobial activity of both formulations by further reducing the microbial flora on the substrate.
- a further advantage of the skin disinfecting formulations of the present invention is the potential to provide long-term residual activity on the applicant's skin to prevent bacteria growth back to the base line of normal skin flora population.
- the skin disinfecting formulations of the present invention will disinfect the skin while also providing emolliency to the skin. Further, the skin disinfecting formulations of the present invention can also be used as a general purpose hand wash to decontaminate the hands of healthcare professionals before examining any patient.
- the typical and/or commonly used scrub solutions contain chemical compounds such as iodine, chlorhexidine gluconate (CHG), PCMX and hexachlorophene. All of these chemical compounds disinfect the skin as well as bind to the skin, thus providing persistent activity. Healthcare professionals may also use the skin disinfecting formulation of the present invention throughout the day. Since health care professionals scrub and wash their hands many times a day, the chemical compounds may buildup on their skin and accumulate through out the day. The intended use of the present invention includes rinsing off the hands and forearms with water to remove any residual chemical build up. Therefore the skin disinfecting formulations of the present invention would be ideal for both routine use throughout the day and as a final wash before leaving the work place.
- chemical compounds such as iodine, chlorhexidine gluconate (CHG), PCMX and hexachlorophene. All of these chemical compounds disinfect the skin as well as bind to the skin, thus providing persistent activity. Healthcare professionals may also use the skin disinfecting formulation of the present invention throughout
- the formulations of the present invention provide substantially effective skin disinfecting properties with the use of alcohol in the formulations as well as being mild and gentle to the skin, and substantially effective against microorganisms.
- Antimicrobial formulations of the present invention are typically packaged in a container. Typically, a foot pump is used to create an increased pressure inside the closed container. The positive pressure difference across the container wall results in the solution being forced up a solution delivery straw.
- Such a formula must therefore satisfy certain physical requirements, which include: viscosity in the range of 0.1-2.5 Pa ⁇ s (100-2500 cps); alcohol as an active ingredient in the range of 60-95% w/w; and antimicrobial agents in a preservative range of 0.001-5.0% w/w.
- the formulation must be efficacious and non-irritating when used. With these parameters in mind the present invention provides an alcohol scrub with greater than 60% alcohol that is effective against microorganisms and causes rapid bacterial reduction.
- the skin disinfecting formulation of the present invention comprises an alcohol, a thickening agent, an emulsifier, a preservative, a moisturizer and/or emollient and water.
- the skin disinfecting formulations may further comprise a fragrance and/or a colorant.
- an alcohol is preferably used in the skin disinfecting formulations because of the inherent bactericidal properties.
- a concentration of alcohol over 60% is an effective germicidal agent. It kills gram-positive, gram-negative bacteria, fungi, mold and a variety of viruses.
- the potent activity of alcohol against microorganisms is due to its denaturation of proteins and enzymes and cellular dehydration.
- the more concentrated the alcohol solution the more potent the antimicrobial effect.
- increasing the alcohol concentration has the deleterious effect of increasing the level of skin irritancy on healthcare workers using the solution.
- the present invention describes a formulation with an alcohol concentration of 70% without an increase in skin irritancy.
- An alcohol for use in the skin disinfecting formulation includes, but is not limited to, isopropyl alcohol, ethanol and n-propyl alcohol.
- the preferred alcohol for use in the skin disinfecting formulations is isopropanol and ethanoL
- ethyl alcohol may be present in the skin disinfecting formulation in an amount from 60 to 95 weight percent, and most preferably at 70 weight percent.
- Thickening agents are used in the skin disinfecting formulations to adjust the viscosity and stability of the formulations. Generally, due to the use of alcohol as a solvent, the typical thickening agent of the present invention remains soluble in alcohol concentration up to at least 70%.
- the thickening agents used in the present invention are cationic polymers. Typical cationic thickening agents include cellulosic materials such as starch, methocel (methyl cellulose ethers) and hydroxycellulose.
- hydrophobic thickeners provide cellulose compositions that improve the biocidal activity of the composition due to the minimum amount of water absorbed from the composition during the thickening process. Thickeners that are less hydrophobic may cause the skin disinfecting formulations to be turbid or milky because the skin disinfecting formulations may precipitate if there is not sufficient water in the composition.
- a suitable thickening agent, for skin disinfecting formulations is hydroxypropyl methylcellulose, METHOCEL® (a trademark of the Dow Chemical Company, Midland, Mich.) sold by The Dow Chemical Company.
- METHOCEL® thickener is 91% hydroxypropyl methyl cellulose which dissolves in aqueous alcohol solution, is nonionic, and is a highly efficient water retention agent.
- the thickening agent may be present in the skin disinfecting formulations in an amount from 0 to 3 weight percent and most preferably at 1 weight percent
- An emulsifier is typically used in the skin disinfecting formulations to disperse oily emollients in water solution. More importantly, an emulsifier is a solubilizer.
- a suitable cationic emulsifier for the skin disinfecting formulation is Incroquat Behenyl® (Trademark of Croda, Inc., Parsippany, NJ) sold by Croda, Inc.
- Incroquat Behenyl® is a compound of 25% active solution of behenyl trimonium methosulfate in cetearyl alcohol and is available in flaked/pastel form.
- This cationic polymer is a very active conditioning agent and bonds to skin through the native negative charge on the skin.
- a second suitable emulsifier available from Croda, Inc. is Incroquat CR Concentrate, which consists of cetearyl alcohol, PEG-40 Castor Oil, and stearalkonium chloride.
- the Incroquat CR Concentrate is one part formulating aid and one part conditioner and self emulsifier. Incroquat CR concentrate will produce a creamy feel, while rinsing and conditioning efficiently.
- a combination of these two cationic emulsifers is preferred.
- the combination provides a smooth after feel and neutralizes the static charge of the skin especially when used in conjunction with isopropyl palmitate, or Incroquat B65C® or Incroquat CT30®, all available from Croda, Inc.
- Alcohol is an excellent antimicrobial agent and will preserve the skin disinfecting formulation very well. However, when the formulation is applied to the skin, the alcohol will evaporate after a period of time. Thus, a small amount of a non-volatile organic antimicrobial agent may be added to the skin disinfecting formulation to preserve the antimicrobial effect of the formulation for an extended period of time.
- the p reservative is selected so as not to upset desirable physical and chemical properties of human skin.
- a properly se lected preservative maintains stability under use and storage conditions (pH, temperature, light, etc.), for a required length of time. It will also prevent the growth of microbes and/or is effective in killing microbes to achieve a continuing antimicrobial effect.
- a suitable preservative may be selected from the class of phenolics such as parachlorometaxylenol, or bis-biguanides such as CHG, chlorhexidine diacetate or Quaterium class such as Benzethonium chloride, benzalkonium chloride.
- Hexetidine, Germaben II®, Kathon CG ®, Triclosan are other antimicrobial agents that may also be suitable as preservatives.
- Hyamine 3500 a trademark of Lonza, Inc., (Fair Lawn, NJ) available from Lonza, Inc., CHG is available from Xttrium laboratories, (Chicago, IL) and Germaben II is available from Sutton Laboratories, (Chatham, NJ).
- Two other preservatives popular in the cosmetics industry are methylparaben and propylparaben. These chemicals are available from Mallinckrodt Chemical Company (St.Louis, MO).
- the preservative may be present in the skin disinfecting formulations in an amount from 0 to 5 weight percent and most preferably at 0.5 weight percent. In an even more preferred embodiment combinations of two or more preservative compounds are present in the formulation.
- Emollients in their physical form are thin liquids, oils of various viscosities, fatty solids or waxes. Hydrocarbons function essentially as emollients by virtue of their ability to lubricate and/or hold water at the skin surface due to their relative occlusivity. Mineral oil is such a fluid. Some emollients are hydrophilic (glycerin, propylene glycol) and are water soluble lubricants and humectants. Since emollients may be fatty chemicals, oily or waxy in nature, they can impart barrier properties to formulations and are then referred to as moisturizers.
- Moisturizers are substances which provide external lubricant behavior, such as to soften and soothe the skin because they encourage skin water retention.
- the function of the moisturizer and/or emollient in the skin disinfecting formulation is to provide relief for dry and sensitive skin. Therefore, chapping of the skin may be prevented. In addition, the moisturizer and/or emollient does not leave a tacky after feel on the skin.
- Suitable moisturizers and/or emollients in the skin disinfecting formulations include isopropyl palmitate, lanolin, derivatives of lanolin such as the ethoxylated acetylated alcohol and surface active alcohol derivatives of lanolin, propylene glycol, polypropylene glycol, polyethylene glycol, mineral oils, squalane, fatty alcohols, glycerin, and silicons such as dimethicone, cyclomethicone, simethicone.
- Preferred moisturizers and/or emollients are selected from lanolin derivatives, polyols and cetylethers.
- the moisturizer and/or emollient in the skin disinfecting formulations is a combination of mineral oil, dimethicone, glycerine, isopropyl palmitate.
- moisturizers and/or emollients are present in the skin disinfecting formulations in an amount from 0.05 to 5 weight percent and most preferably at 1.0 weight percent.
- ingredients which are conventional or desirable for aesthetic purposes may also be added to the skin disinfecting formulations as long as they do not adversely affect the overall properties of the formulation.
- Such ingredients may include a perfume or fragrance to provide a pleasing scent or a dye to provide a characteristic color.
- the skin disinfecting formulations of the invention may be prepared in 4 individual Steps and in three separate vessels.
- Step 1 involves the mixing of the alcohol, water, and thickening agent.
- the thickening agent (Methocel Cellulose) is dispersed in the alcohol/water mixture at ambient temperatures. The subsequent mixture is agitated until the thickening agent is fully dissolved and no granulation remains.
- step 2 a separate container is used which is suitable for heating the various emulsifiers and moisturizing agents.
- the emulsifier mixture may include one or more of the following methylparaben, propylparaben, isopropyl palpitate, mineral oil, incroquat CR, dimethicone-350, and Incroquat BTMS.
- the emulsifying agents are heated to 60-85°C with mixing until all the ingredients are melted and thoroughly mixed.
- Step 3 a vessel of water and glycerin is heated to 50-80°C with mixing.
- the heated ingredients from Step 2 and any fragrance or colorant is then added with vigorous mixing to the glycerin/water solution of Step 3.
- the water/glycerin/emulsifier solution is then cooled to below 35°C with continued mixing.
- Step 4 the water/glycerin/emulsifier mixture in Step 3 is added to the alcohol/water/thickening agent mixture in Step 1 and mixed thoroughly.
- Preservatives are then added to the solution including one or more of the following: benzethonium chloride; benzalkonium chloride; and CHG.
- the solution is mixed continuously until a homogenous mixture is achieved.
- the skin disinfecting formulations of the present invention were prepared with the ingredients as shown in Table I.
- the formulations were mixed in the manner described above.
- ethyl alcohol was used as the primary antimicrobial agent.
- Additional preservatives include benzethonium chloride, benzalkonium chloride, and CHG. Table I.
- Antimicobial Formulation Compositions for the present invention Compositions are listed weight/100 weight solution Ingredient Formula A Formula B Formula C Formula D Formula E Formula F Formula G Formula H Ethyl alcohol 72.188 72.188 76.500 72.188 72.188 72.188 72.188 72.188 72.188 Cellulose (Methocel) 1.005 1.005 1.000 1.005 1.005 1.005 1.005 1.005 Incroquat BTMS 0.100 0.100 0.200 0.200 0.200 0.200 0.200 0.200 0.200 0.200 0.200 0.200 0.200 0.200 0.200 0.200 0.200 Mineral Oil 0.0100 0.0100 0.100 0.100 0.100 Dimethicone - 350 0.010 0.015 0.015 0.015 0.015 0.015 0.015 0.015 0.015 0.015 Benzethonium Chloride 0.099 0.099 0.099 0.099 0.099 0.099 0.099 0.099 0.099 Incroquat CR 0.051 0.050 0.050 0.050 0.0
- Formula C of the present invention was tested for primary dermal irritation and skin sensitization, based upon procedures described in ISO 10993-10: 1995 Standard, "Biological Evaluation of Medical Devices, Part 10-Tests for Irritation and Sensitization.”
- Ten test guinea pigs were patched with the test article and five guinea pigs were patched with a control blank. The bandages and patches were removed after six (6) hours of exposure. After a 24 hour rest period, each site was observed on each animal for erythema and edema. This procedure was repeated once a week for three weeks for a total of three applications. Following a two week rest period, the test animals were topically patched with the appropriate test article containing Formula C and the control blank on the control animals.
- the patches were removed after 6 hours of exposure.
- the dermal patch sites were observed for erythema and edema at 24, 48 and 7 2 h ours after patch removal.
- test results were based upon incidence and severity of the sensitization reaction. Individual animal scores of one (1) or greater in the test group generally indicate sensitization, provided scores of less than one (1) are observed on the control animals. An effect interpreted as "irritation” is generally observed at 24 hours, but diminishes thereafter.
- Table IV Irritancy Test results for Formula C Test Results Primary Dermal Irritation Slight Irritant (Undiluted) Sensitization Non sensitization
- Formulation X is the subject of U.S. -A-6,090,395 and consists generally of a rinse-less 61% ethanol and 1% CHG solution.
- Formulation Y is a 4% CHG solution, and Formulation Z, the subject of U.S. -A-6,110,908 , is a brush-free 70% ethanol solution.
- the formulations were applied to the upper back of twenty-six (26) healthy volunteers daily for twenty-one (21) days, and remained in contact with the skin for twenty-four (24) hours with each application. Dermal irritation was evaluated daily by a dermatologist using the following scoring scale:
- Formula C was classified as a "mild material" under occlusive conditions.
- the irritation score was not different for Formula Y, but significantly less than the patented formulations X and Z.
- Formula C and the three commercial test formulations w ere applied to a na ⁇ ve site, and irritancy scores were taken at forty-eight (48) and ninety-six (96) hours post application to determine the level of contact sensitization.
- the scores are presented in Table VI. TABLE VI Formula C Formula X Formula Y Formula Z Scores 0 4.5 0 2.5
- Formula C as an antimicrobial formulation was tested at 70% ethyl alcohol.
- the study evaluated the effectiveness of Formula C solution as a surgical scrub and hand antiseptic against broad-spectrum microorganisms.
- the study brought into contact Formula C with a population of organisms for a specific period of time at a specific temperature.
- the organisms included gram positive and gram negative bacteria, yeast, and molds that are commonly implicated in surgical wound infections.
- the percent reduction from the initial population was calculated for each of the organisms. The population reduction is presented in Table VII. TABLE VII.
- Formulations C, D, F, and G, of the present invention with moisturizer provided rapid antimicrobial kill of broad-spectrum microorganisms with greater than log 6 microbial kill in 15 seconds.
- the patented formulations X ( US -A-6,090,395 ) and Z ( US -A-6,110,908 ) provided less effective kill rates depending on the species of bacteria examined.
- the present invention showed an uncommon effectiveness against one of the more deleterious Staphylococcus strains, Staphylococcus aureus.
- All formulations of the present invention had a greater than log 6 reduction of Staphylococcus aureus., while Formula X managed a log reduction of greater than 5, an order of magnitude less effective and formula Z was less effective by two orders of magnitude having a log reduction of greater than 4.
- Formula C was used as the (test solution), and 70% ethyl alcohol solution as the (control solution) were diluted with a trypticase soy broth microbial growth media. Subsequent dilutions had the concentration calculated in ppm. Each concentration was challenged with an equal volume of microbial inoculums. After incubation the lowest concentration showing "No-Growth" was recorded as the Minimum Inhibitory Concentration. At full strength both Formula C and a 70% ethyl alcohol solution contain 70,000 ppm. Table VIII.
- TFM Tentative Final Monograph
- Formula C produced significant immediate log reduction 1.76 on test day 1, 2.31 on test day 2 and 3.03 on test day five (5).
- the microorganism population from the Formula C sample was taken six and a half (6.5) hours following the scrub innoculation, and did not return to pro-scrub microbial baseline levels.
- This data indicates that Formula C met the criteria indices of the FDA Tentative Final Monograph for a surgical scrub.
- the test data also confirmed that the integrated product of Formula C and 4% CHG is the best practice for a surgical scrub.
- the integrated products produced significant immediate log reduction 2.07 on test day 1, 2.98 on test day 2 and 3.47 on test day 5.
- test data also indicates that Formula X ( US-A-6,090,395 ) and Formula Z ( US-A-6,110,908 ) did not meet the criteria indices of the FDA as specified in the Tentative Final Monograph for a surgical scrub product.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
Description
- The present invention relates to an antimicrobial composition for use as an emollient alcohol based skin disinfectant that will not irritate or dry the skin. The skin disinfecting formulations of the present invention are particularly useful in the healthcare profession as a hand healthcare preparation or as a pre-surgical scrub without requiring a secondary emollient application.
- Hand washing by healthcare professionals is an essential component of infection control activities. Healthcare professionals attending to patient care wash their hands to control the spread of infection from patient to patient and surgical procedures are routinely proceeded by surgical hand scrubbing and patient pre-operative skin preparation.
- Hand washing procedures are performed in several ways. Several procedures include an ordinary antimicrobial bar soap, a skin disinfecting alcohol based preoperative preparation agent, or rubbing alcohol The repeated use of these procedures causes the hands to become rough, dry and cracked.
- The majority of the commercially available scrubs include detergents and an antimicrobial agent or a preservative. Examples of the antimicrobial or preservative agents include iodine formulations, iodophors, phenolic compounds such as parachlorometaxylenol and hexachlorophene and bis-biguanides such as chlorhexidine gluconate (CHG).
WO-A-01/41567
US-A-6,110,908 describes an antiseptic formulation for topical application to animal skin, comprising an antimicrobial alcohol selected from the group consisting of ethanol, isopropanol, n-propanol and mixtures thereof, an antimicrobial lipid selected from the group consisting of free fatty acids having from six to eighteen carbons, glycerol monolaurate and mixtures thereof and zinc pyrithione.
EP-A-0689767 discloses a skin disinfecting formulation for use as a skin washing agent, comprising an alcohol, a block copolymer, a foaming surfactant, an emulsifier, a cleaning agent, a polyalkylene glycol, an emollient and water which is described as providing anti microbial effectiveness to the skin. - Although alcohol in general is recognized for its very effective disinfecting properties, it is not used directly with skin or in scrab formulations because it is a defatting agent. When alcohol is applied to the human skin, it makes it very dry, often developing chapped and cracked skin. Furthermore, it is difficult to formulate a detergent solution with alcohol that will lather like ordinary soaps and detergents when used with water. However, due to the disinfecting properties of alcohol, it is desirable to produce a skin disinfecting formulation with alcohol which is mild and gentle to the skin, and is effective at controlling microorganism populations on the skin.
- The present invention is a skin disinfecting formulation that provides antimicrobial effectiveness and is mild and gentle to human skin. The skin disinfecting formulation desirably comprises an alcohol, a thickening agent, a preservative, an emulsifier, a moisturizer and/or emollient and water.
- Preferably, the skin disinfecting formulation may further comprise a colorant or a fragrance.
In particular, the present invention provides the following: - 1. An antimicrobial composition comprising:
- a) an alcohol selected from the group consisting of ethyl alcohol, isopropyl alcohol and n-propyl alcohol and mixtures thereof in an amount from 60 to 95 weight percent of the total composition;
- b) a preservative in an amount from 0.001 to 5.0 weight percent of the total composition, wherein the preservative is one or more of the compounds selected from the group consisting of parachlorometaxylenol, phenoxy ethanol, benzalkonium chloride, benzethonium chloride, chlorhexidine gluconate, chlorhexidine diactetate, hexetidine, triclosan;
- c) a thickening agent in an amount from 0.01 to 3 weight percent of the total composition wherein said thickening agent is hydroxypropyl methylcellulose;
- d) a moisturizer and/or emollient in an amount from 0.005 to 5.0 weight percent of the total composition, wherein said moisturizer and/or emollient is one or more of the compounds selected from the group consisting of mineral oil, dimethicone, glycerin, isopropyl plamitate, propylene glycol, petrolatum, and squalane;
- e) a cationic emulsifier in an amount from 0.01 to 3 weight percent of the total composition wherein the cationic emulsifier is selected from
- (i) a 25 % active solution of behenyl trimonium methosulfate in cetearyl alcohol,
- (ii) a concentrate consisting of cetearyl alcohol, PEG-40 castor oil, and stearalkonium chloride, and
- (iii) a combination of (i) and (ii);
- f) water in an amount from 6 to 30 weight percent.
- 2. The composition of item 1 wherein the preservative is a mixture of benzenethonium chloride from 0.02 to 1.0 percent by weight and benzalkonium chloride from 0.02 to 1.0 percent by weight and chlorhexidine gluconate from 0.01 to 2.0 percent by weight.
- 3. The composition of item 1 which additionally contains an effective amount of diazolidinyl urea and 3-iodo-propynylbutyl carbamate.
- 4. The composition of item 3 wherein the total amount of diazolidinyl urea and 3-iodo-propynylbutylcarbamate is from 0.05 to 0.5 percent by weight.
- 5. The composition of item 3 which additionally contains an effective amount; methyl paraben, propyl paraben, and propylene glycol.
- 6. The composition of item 5 wherein the total amount of diazolindinyl urea, methyl paraben propyl paraben, and propylene glycol is from 0.05 to 2.0 percent by weight.
- 7. A method of disinfecting a substrate comprising the step of applying to the substrate an effective amount of the antimicrobial composition of any of items 1 to 6.
- 8. The method of item 7 wherein the substrate is the hand.
- The skin disinfecting formulations of the present invention are useful in providing substantial antimicrobial effectiveness and surprisingly, provide substantial non-irritancy to the skin in view of the alcohol component of the formulations.
- Another attribute of the skin disinfecting formulation is its ability to not dry the skin.
- Another advantage of the skin disinfecting formulation is the compatibility with other Chlorohexidine Gluconate products, which enhances the antimicrobial activity of both formulations by further reducing the microbial flora on the substrate.
- A further advantage of the skin disinfecting formulations of the present invention is the potential to provide long-term residual activity on the applicant's skin to prevent bacteria growth back to the base line of normal skin flora population.
- The skin disinfecting formulations of the present invention will disinfect the skin while also providing emolliency to the skin. Further, the skin disinfecting formulations of the present invention can also be used as a general purpose hand wash to decontaminate the hands of healthcare professionals before examining any patient.
- Healthcare professionals perform a routine hand scrubbing procedure many times a day. The typical and/or commonly used scrub solutions contain chemical compounds such as iodine, chlorhexidine gluconate (CHG), PCMX and hexachlorophene. All of these chemical compounds disinfect the skin as well as bind to the skin, thus providing persistent activity. Healthcare professionals may also use the skin disinfecting formulation of the present invention throughout the day. Since health care professionals scrub and wash their hands many times a day, the chemical compounds may buildup on their skin and accumulate through out the day. The intended use of the present invention includes rinsing off the hands and forearms with water to remove any residual chemical build up. Therefore the skin disinfecting formulations of the present invention would be ideal for both routine use throughout the day and as a final wash before leaving the work place.
- Surprisingly, the formulations of the present invention provide substantially effective skin disinfecting properties with the use of alcohol in the formulations as well as being mild and gentle to the skin, and substantially effective against microorganisms. Antimicrobial formulations of the present invention are typically packaged in a container. Typically, a foot pump is used to create an increased pressure inside the closed container. The positive pressure difference across the container wall results in the solution being forced up a solution delivery straw. Such a formula must therefore satisfy certain physical requirements, which include: viscosity in the range of 0.1-2.5 Pa·s (100-2500 cps); alcohol as an active ingredient in the range of 60-95% w/w; and antimicrobial agents in a preservative range of 0.001-5.0% w/w. In addition, the formulation must be efficacious and non-irritating when used. With these parameters in mind the present invention provides an alcohol scrub with greater than 60% alcohol that is effective against microorganisms and causes rapid bacterial reduction.
- The skin disinfecting formulation of the present invention comprises an alcohol, a thickening agent, an emulsifier, a preservative, a moisturizer and/or emollient and water. The skin disinfecting formulations may further comprise a fragrance and/or a colorant.
- An alcohol is preferably used in the skin disinfecting formulations because of the inherent bactericidal properties. Generally, a concentration of alcohol over 60% is an effective germicidal agent. It kills gram-positive, gram-negative bacteria, fungi, mold and a variety of viruses. The potent activity of alcohol against microorganisms is due to its denaturation of proteins and enzymes and cellular dehydration. Typically, the more concentrated the alcohol solution the more potent the antimicrobial effect. However, increasing the alcohol concentration has the deleterious effect of increasing the level of skin irritancy on healthcare workers using the solution. Surprisingly, the present invention describes a formulation with an alcohol concentration of 70% without an increase in skin irritancy.
- An alcohol for use in the skin disinfecting formulation includes, but is not limited to, isopropyl alcohol, ethanol and n-propyl alcohol.
- The preferred alcohol for use in the skin disinfecting formulations is isopropanol and ethanoL Preferably, ethyl alcohol may be present in the skin disinfecting formulation in an amount from 60 to 95 weight percent, and most preferably at 70 weight percent.
- Thickening agents are used in the skin disinfecting formulations to adjust the viscosity and stability of the formulations. Generally, due to the use of alcohol as a solvent, the typical thickening agent of the present invention remains soluble in alcohol concentration up to at least 70%. The thickening agents used in the present invention are cationic polymers. Typical cationic thickening agents include cellulosic materials such as starch, methocel (methyl cellulose ethers) and hydroxycellulose.
- It is believed that hydrophobic thickeners provide cellulose compositions that improve the biocidal activity of the composition due to the minimum amount of water absorbed from the composition during the thickening process. Thickeners that are less hydrophobic may cause the skin disinfecting formulations to be turbid or milky because the skin disinfecting formulations may precipitate if there is not sufficient water in the composition.
- A suitable thickening agent, for skin disinfecting formulations is hydroxypropyl methylcellulose, METHOCEL® (a trademark of the Dow Chemical Company, Midland, Mich.) sold by The Dow Chemical Company. METHOCEL® thickener is 91% hydroxypropyl methyl cellulose which dissolves in aqueous alcohol solution, is nonionic, and is a highly efficient water retention agent.
- preferably, the thickening agent may be present in the skin disinfecting formulations in an amount from 0 to 3 weight percent and most preferably at 1 weight percent
- An emulsifier is typically used in the skin disinfecting formulations to disperse oily emollients in water solution. More importantly, an emulsifier is a solubilizer.
- A suitable cationic emulsifier for the skin disinfecting formulation is Incroquat Behenyl® (Trademark of Croda, Inc., Parsippany, NJ) sold by Croda, Inc. Incroquat Behenyl® is a compound of 25% active solution of behenyl trimonium methosulfate in cetearyl alcohol and is available in flaked/pastel form. This cationic polymer is a very active conditioning agent and bonds to skin through the native negative charge on the skin.
- A second suitable emulsifier available from Croda, Inc. is Incroquat CR Concentrate, which consists of cetearyl alcohol, PEG-40 Castor Oil, and stearalkonium chloride. The Incroquat CR Concentrate is one part formulating aid and one part conditioner and self emulsifier. Incroquat CR concentrate will produce a creamy feel, while rinsing and conditioning efficiently.
- A combination of these two cationic emulsifers is preferred. The combination provides a smooth after feel and neutralizes the static charge of the skin especially when used in conjunction with isopropyl palmitate, or Incroquat B65C® or Incroquat CT30®, all available from Croda, Inc.
- Alcohol is an excellent antimicrobial agent and will preserve the skin disinfecting formulation very well. However, when the formulation is applied to the skin, the alcohol will evaporate after a period of time. Thus, a small amount of a non-volatile organic antimicrobial agent may be added to the skin disinfecting formulation to preserve the antimicrobial effect of the formulation for an extended period of time.
- The p reservative is selected so as not to upset desirable physical and chemical properties of human skin. A properly se lected preservative maintains stability under use and storage conditions (pH, temperature, light, etc.), for a required length of time. It will also prevent the growth of microbes and/or is effective in killing microbes to achieve a continuing antimicrobial effect.
- A suitable preservative may be selected from the class of phenolics such as parachlorometaxylenol, or bis-biguanides such as CHG, chlorhexidine diacetate or Quaterium class such as Benzethonium chloride, benzalkonium chloride. Hexetidine, Germaben II®, Kathon CG ®, Triclosan are other antimicrobial agents that may also be suitable as preservatives. Benzethonium chloride and benzalkonium chloride as Hyamine 3500 a trademark of Lonza, Inc., (Fair Lawn, NJ) available from Lonza, Inc., CHG is available from Xttrium laboratories, (Chicago, IL) and Germaben II is available from Sutton Laboratories, (Chatham, NJ). Two other preservatives popular in the cosmetics industry are methylparaben and propylparaben. These chemicals are available from Mallinckrodt Chemical Company (St.Louis, MO).
- Preferably, the preservative may be present in the skin disinfecting formulations in an amount from 0 to 5 weight percent and most preferably at 0.5 weight percent. In an even more preferred embodiment combinations of two or more preservative compounds are present in the formulation.
- Emollients in their physical form are thin liquids, oils of various viscosities, fatty solids or waxes. Hydrocarbons function essentially as emollients by virtue of their ability to lubricate and/or hold water at the skin surface due to their relative occlusivity. Mineral oil is such a fluid. Some emollients are hydrophilic (glycerin, propylene glycol) and are water soluble lubricants and humectants. Since emollients may be fatty chemicals, oily or waxy in nature, they can impart barrier properties to formulations and are then referred to as moisturizers.
- Moisturizers are substances which provide external lubricant behavior, such as to soften and soothe the skin because they encourage skin water retention.
- The function of the moisturizer and/or emollient in the skin disinfecting formulation is to provide relief for dry and sensitive skin. Therefore, chapping of the skin may be prevented. In addition, the moisturizer and/or emollient does not leave a tacky after feel on the skin.
- Suitable moisturizers and/or emollients in the skin disinfecting formulations include isopropyl palmitate, lanolin, derivatives of lanolin such as the ethoxylated acetylated alcohol and surface active alcohol derivatives of lanolin, propylene glycol, polypropylene glycol, polyethylene glycol, mineral oils, squalane, fatty alcohols, glycerin, and silicons such as dimethicone, cyclomethicone, simethicone. Preferred moisturizers and/or emollients are selected from lanolin derivatives, polyols and cetylethers. Most preferably, the moisturizer and/or emollient in the skin disinfecting formulations is a combination of mineral oil, dimethicone, glycerine, isopropyl palmitate.
- Preferably, moisturizers and/or emollients are present in the skin disinfecting formulations in an amount from 0.05 to 5 weight percent and most preferably at 1.0 weight percent.
- Other ingredients which are conventional or desirable for aesthetic purposes may also be added to the skin disinfecting formulations as long as they do not adversely affect the overall properties of the formulation. Such ingredients may include a perfume or fragrance to provide a pleasing scent or a dye to provide a characteristic color.
- The skin disinfecting formulations of the invention may be prepared in 4 individual Steps and in three separate vessels. Step 1 involves the mixing of the alcohol, water, and thickening agent. The thickening agent (Methocel Cellulose) is dispersed in the alcohol/water mixture at ambient temperatures. The subsequent mixture is agitated until the thickening agent is fully dissolved and no granulation remains. In step 2, a separate container is used which is suitable for heating the various emulsifiers and moisturizing agents. The emulsifier mixture may include one or more of the following methylparaben, propylparaben, isopropyl palpitate, mineral oil, incroquat CR, dimethicone-350, and Incroquat BTMS. The emulsifying agents are heated to 60-85°C with mixing until all the ingredients are melted and thoroughly mixed. In Step 3 a vessel of water and glycerin is heated to 50-80°C with mixing. The heated ingredients from Step 2 and any fragrance or colorant is then added with vigorous mixing to the glycerin/water solution of Step 3. The water/glycerin/emulsifier solution is then cooled to below 35°C with continued mixing. Finally, in Step 4 the water/glycerin/emulsifier mixture in Step 3 is added to the alcohol/water/thickening agent mixture in Step 1 and mixed thoroughly. Preservatives are then added to the solution including one or more of the following: benzethonium chloride; benzalkonium chloride; and CHG. The solution is mixed continuously until a homogenous mixture is achieved.
- The skin disinfecting formulations of the present invention were prepared with the ingredients as shown in Table I. The formulations were mixed in the manner described above. In each formulation, ethyl alcohol was used as the primary antimicrobial agent. Additional preservatives include benzethonium chloride, benzalkonium chloride, and CHG.
Table I. Antimicobial Formulation Compositions for the present invention Compositions are listed weight/100 weight solution Ingredient Formula A Formula B Formula C Formula D Formula E Formula F Formula G Formula H Ethyl alcohol 72.188 72.188 76.500 72.188 72.188 72.188 72.188 72.188 Cellulose (Methocel) 1.005 1.005 1.000 1.005 1.005 1.005 1.005 1.005 Incroquat BTMS 0.100 0.100 0.200 0.200 0.200 0.200 0.200 0.200 Mineral Oil 0.0100 0.0100 0.100 0.100 0.100 Dimethicone - 350 0.010 0.015 0.015 0.015 0.015 0.015 0.015 Benzethonium Chloride 0.099 0.099 0.099 0.099 0.099 0.099 0.099 0.099 Incroquat CR 0.051 0.050 0.050 0.050 0.050 0.050 Benzalkonium Chloride 0.099 0.099 0.099 0.099 0.099 0.099 0.099 0.099 Glycerin 0.708 0.700 0.700 0.700 0.000 0.000 0.700 0.700 Germaben II 0.030 0.030 0.030 0.030 0.030 0.030 0.030 Purified Water 25.196 25.458 20.905 25.223 25.423 25.298 25.141 25.223 CHG (20% Solution) 0.090 0.090 0.090 0.090 0.090 0.090 0.090 0.090 Isopropyl Palmitate 0.202 0.200 0.200 0.200 0.200 0.200 0.200 0.200 Fragrance 0.030 0.030 Hexetidine 0.002 0.002 0.002 0.002 0.002 lincroquat B65C 0.050 0.050 Propylene Glycol 0.500 0.700 Triclosan 0.002 Petrolatum 0.202 Incroquat CTC30 0.100 Squalane 0.025 Total 100.000 100.000 100.000 100.000 100.000 100.000 100.000 100.000 - Formula C of the present invention was tested for primary dermal irritation and skin sensitization, based upon procedures described in ISO 10993-10: 1995 Standard, "Biological Evaluation of Medical Devices, Part 10-Tests for Irritation and Sensitization." Ten test guinea pigs were patched with the test article and five guinea pigs were patched with a control blank. The bandages and patches were removed after six (6) hours of exposure. After a 24 hour rest period, each site was observed on each animal for erythema and edema. This procedure was repeated once a week for three weeks for a total of three applications. Following a two week rest period, the test animals were topically patched with the appropriate test article containing Formula C and the control blank on the control animals. The patches were removed after 6 hours of exposure. The dermal patch sites were observed for erythema and edema at 24, 48 and 7 2 h ours after patch removal. E ach animal w as assessed for a sensitization response based on dermal observation scores illustrated in Table II.
Table II: Dermal Application Observations ANIMAL# 24 Hours 48 Hours 72 Hours ER ED ER ED ER ED TEST GROUP 2078 1 0 0 0 0 0 2079 0 0 1 0 1 0 2080 0 0 1 0 0 0 2081 0 0 0 0 0 0 2082 0 0 0 0 0 0 2083 0 0 0 0 0 0 2084 0 0 1 0 0 0 2085 0 0 0 0 0 0 2086 0 0 0 0 0 0 2087 1 0 0 0 1 0 Total of Scores 2 3 2 Severity (Total/10) 0.2 0.3 0.2 Incidence% 20% 30% 20% NEGATIVE CONTROL GROUP 2088 0 0 0 0 0 0 2089 0 0 0 0 0 0 2090 0 0 0 0 0 0 2091 0 0 0 0 0 0 2092 0 0 0 0 0 0 Total of Scores 0 0 0 0 0 0 Severity (Total/10) 0 0 0 0 0 0 Incidence% 0% 0% 0% - The application sites were observed for irritation and sensitization reaction, as indicated by erythema and edema. The sites were gently wiped with a 70% alcohol soaked gauge sponge prior to each scoring period. The scoring criteria are listed below in Table III.
Table III: Dermal Observation Scoring ERYTHEMA EDEMA 0 = No erythema 0 = No edema 1 = Slight erythema 1 = Slight edema 2 = Well defined erythema 2 = Well defined edema 3 = Moderate erythema 3 = Moderate edema 4 = Severe erythema to slight eschar formation 4 = Severe edema - The test results were based upon incidence and severity of the sensitization reaction. Individual animal scores of one (1) or greater in the test group generally indicate sensitization, provided scores of less than one (1) are observed on the control animals. An effect interpreted as "irritation" is generally observed at 24 hours, but diminishes thereafter. The results are summarized in Table IV.
Table IV. Irritancy Test results for Formula C Test Results Primary Dermal Irritation Slight Irritant (Undiluted) Sensitization Non sensitization - The results of the test indicate that Formula C has a 20% incidence dermal response with a 0.2 severity index at the 24 hour time point; a 30% incidence with a 0.3 severity index at the 48 hour point; and a 20% incidence with a 0.2 severity index at the 72 hour point. However, the pattern of responses was irregular and did not repeat in every animal from 24 to 48 hours and therefore the response at 24 hours was categorized as an irritation. While a sensitization reaction could not be completely ruled out, Formula C had a slight potential for irritation when applied in semi-occluded conditions and a very low potential for sensitization, it was therefore classified as acceptable in regard to dermal sensitization.
- The relative skin irritation potential of Formula C solution was compared with three commercially available skin disinfecting formulations (Formulas X, Y and Z). Formulation X is the subject of
U.S. -A-6,090,395 and consists generally of a rinse-less 61% ethanol and 1% CHG solution. Formulation Y is a 4% CHG solution, and Formulation Z, the subject ofU.S. -A-6,110,908 , is a brush-free 70% ethanol solution. The formulations were applied to the upper back of twenty-six (26) healthy volunteers daily for twenty-one (21) days, and remained in contact with the skin for twenty-four (24) hours with each application. Dermal irritation was evaluated daily by a dermatologist using the following scoring scale: - 0 = negative
- + = equivocal reaction (0.5)
- 1 = erythema
- 2 = erythema and induration
- 3 = erythema, induration and vesicles
- 4 = bullae
- Formula C was classified as a "mild material" under occlusive conditions. The irritation score was not different for Formula Y, but significantly less than the patented formulations X and Z.
- Formula C and the three commercial test formulations w ere applied to a naïve site, and irritancy scores were taken at forty-eight (48) and ninety-six (96) hours post application to determine the level of contact sensitization. The scores are presented in Table VI.
TABLE VI Formula C Formula X Formula Y Formula Z Scores 0 4.5 0 2.5 - The results of the test again showed that the formulation of the present invention, formula C, had no potential for contact sensitization. The scores in Table VI are the sum of the scores at 48 and 96 hours only.
- The efficacy of Formula C as an antimicrobial formulation was tested at 70% ethyl alcohol. The study evaluated the effectiveness of Formula C solution as a surgical scrub and hand antiseptic against broad-spectrum microorganisms. The study brought into contact Formula C with a population of organisms for a specific period of time at a specific temperature. The organisms included gram positive and gram negative bacteria, yeast, and molds that are commonly implicated in surgical wound infections. The percent reduction from the initial population was calculated for each of the organisms. The population reduction is presented in Table VII.
TABLE VII. In-vitro Time Kill Study at Full Strength (Log Reduction) Formula Formula C Formula D Formula F Formula G Formula X Formula Z Gram Positive Bacteria Staphylococcus aureus 15 seconds >6 log >6 log >6 log >6 log >5 log >4 log 30 seconds >6 log >6 log >6 log >6 log >5 log >4 log Staphylococcus epidermidis 15 seconds >6 log >6 log >6 log >6 log >6 log >4 log 30 seconds >6 log >6 log >6 log >6 log >6 log >4 log Gram negative bacteria Enterococcus faecalis 15 seconds >6 log >6 log >6 log >6 log >6 log >4 log 30 seconds >6 log >6 log >6 log >6 log >6 log >4 log Escherichia coli 15 seconds >6 log >6 log >6 log >6 log >6 log >3 log 30 seconds >6 log >6 log >6 log >6 log >6 log >3 log Enterobacter cloacae 15 seconds >6 log >6 log >6 log >6 log >6 log >4 log 30 seconds >6 log >6 log >6 log >6 log >6 log >4 log Pseudomonas aeruginosa 15 seconds >6 log >6 log >6 log >6 log >6 log >4 log 30 seconds >6 log >6 log >6 log >6 log >6 log >4 log Proteus vulgaris 15 seconds >6 log >6 log >6 log >6 log >6 log >4 log 30 seconds >6 log >6 log >6 log >6 log >6 log >4 log Klebsiella pneumoniae 15 seconds >6 log >6 log >6 log >6 log >6 log >4 log 30 seconds >6 log >6 log >6 log >6 log >6 log >4 log Serratia marcescens 15 seconds >6 log >6 log >6 log >6 log >6 log >4 log 30 seconds >6 log >6 log >6 log >6 log >6 log >4 log Yeast Candida albicans 15 seconds >6 log >6 log >6 log >6 log >6 log >4 log 30 seconds >6 log >6 log >6 log >6 log >6 log >4 log - Formulations C, D, F, and G, of the present invention, with moisturizer provided rapid antimicrobial kill of broad-spectrum microorganisms with greater than log 6 microbial kill in 15 seconds. In comparison, the patented formulations X (
US -A-6,090,395 ) and Z (US -A-6,110,908 ) provided less effective kill rates depending on the species of bacteria examined. The present invention showed an uncommon effectiveness against one of the more deleterious Staphylococcus strains, Staphylococcus aureus. All formulations of the present invention had a greater than log 6 reduction of Staphylococcus aureus., while Formula X managed a log reduction of greater than 5, an order of magnitude less effective and formula Z was less effective by two orders of magnitude having a log reduction of greater than 4. - In another study the minimum inhibitory concentration of Formula C was investigated. Formula C was used as the (test solution), and 70% ethyl alcohol solution as the (control solution) were diluted with a trypticase soy broth microbial growth media. Subsequent dilutions had the concentration calculated in ppm. Each concentration was challenged with an equal volume of microbial inoculums. After incubation the lowest concentration showing "No-Growth" was recorded as the Minimum Inhibitory Concentration. At full strength both Formula C and a 70% ethyl alcohol solution contain 70,000 ppm.
Table VIII. Minimum Concentrations of Formula C and 70% Ethyl Alcohol to Exhibit Antimicrobial Activity Organisms ATCC or CI* Formula C 70% ethyl alcohol Acinetobacter baumannii 19606 182ppm 4375ppm Acinetobacter baumannii 061901 Ab1* 273ppm 8750ppm Bacteroides fragilis 25285 273ppm 8750ppm Bacteroides fragilis 061901Bf2* 547ppm 8750ppm Candida albicans 10231 1094ppm 17500ppm Candida albicans 040400Ca2* 1094ppm 17500ppm Candida tropicalis 750 1094ppm 17500ppm Candida parapsilosis 040400Cp2* 1094ppm 17500ppm Enterobacter aerogenes 13048 547ppm 8750ppm Enterobacter aerogenes 040400Ea1* 182ppm 8750ppm Enterococcus faecalis 29212 273ppm 8750ppm Enterococcus faecalis 040400Esp17* 273ppm 8750ppm Enterococcus faecium 51559 183ppm 8750ppm Enterococcus faecium 061901Efm1* 273ppm 8750ppm Escherichia coli 11229 91ppm 8750ppm Escherichia coli 051599Ec* 68ppm 8750ppm Escherichia coli 25922 68ppm 8750ppm Escherichia coli 070399Ec* 137ppm 8750ppm Haemophilus influenzae 19418 183ppm 5833ppm Haemophilus influenzae 121699Hi* 46ppm 5833ppm Klebsiella oxytoca 43165 183ppm 8750ppm Klebsiella oxytoca 061901Kol* 183ppm 8750ppm Klebsiella pneumoniae 13883 68ppm 4375ppm Klebsiella pneumoniae 06190Kpnl* 137ppm 8750ppm Micrococcus luteus 7468 17ppm 8750ppm CI* - Clinical isolate - The data from Table VIII clearly illustrates that Formula C inhibits bacteria growth at a lower concentration than a 70% ethyl alcohol solution. The greater than fifteen fold growth inhibition activity of Formula C is largely attributable to the cocktail of antimicrobial agents used as preservatives.
- Formula C was tested under the US Food and Drug Administration Tentative Final Monograph (TFM) for Effectiveness Testing of a Surgical Hand Scrub. This study evaluates the antimicrobial efficacy of one (1) test product and three (3) reference products for use as surgical scrubs. The procedure followed is described in the TFM for Presurgical Scrub Preparations (FR 59 [116], 17 Jun 94: pp. 31455-31448), with the objective of determining whether the test products would satisfy the critical indices of the TFM, such as:
- An immediate one (1) log10 reduction in microorganisms on Day 1;
- An immediate two (2) log10 reduction in microorganisms on Day 2;
- An immediate three (3) log10 reduction in microorganisms on Day 5;
- And that microbial counts from the samples taken approximately three (3) hours to three (3) hours and thirty (30) minutes AND approximately six (6) hours to six (6) hours and thirty (30) minutes post-scrub not exceed the baseline counts.
- The study was conducted to evaluate the antimicrobial effectiveness of Formula C solution compared to Formulas X and Z, and a combination of Formula C with 4% CHG. The results are presented in Table IX.
Table IX. FDA Approved Hand Scrub Efficacy Test Immediate Log Reduction Formula C Formula C with 4% CHG Formula X Formula Z Day 1 1.76 2.07 1.63 0.35 Day 2 2.31 2.98 2.22 1.21 Day 3 3.03 3.47 2.52 2.75 - The Comparative antimicrobial efficacy test data presented in Table IX, tested four different surgical hand scrubs. The data is reported as the immediate log reduction in microbial counts per hand when sampled one minute following the daily scrub over a five day period. Log reduction relates to a 10-fold or one decimal or 90% reduction in numbers of recoverable bacteria in a test food vehicle, that is a 1 log reduction would reduce the number of bacteria 90%. This means, for example, that 100 bacteria would be reduced to 10 or 10 reduced to 1. Table X represents the percent reduction of bacteria for logs one through five.
Table X. Microbial Log Reduction Log Reduction Chart Log Reduction % Reduction of Bacteria 1 90 2 99 3 99.9 4 99.99 5 99.999 - Formula C produced significant immediate log reduction 1.76 on test day 1, 2.31 on test day 2 and 3.03 on test day five (5). The microorganism population from the Formula C sample, was taken six and a half (6.5) hours following the scrub innoculation, and did not return to pro-scrub microbial baseline levels. This data indicates that Formula C met the criteria indices of the FDA Tentative Final Monograph for a surgical scrub. The test data also confirmed that the integrated product of Formula C and 4% CHG is the best practice for a surgical scrub. The integrated products produced significant immediate log reduction 2.07 on test day 1, 2.98 on test day 2 and 3.47 on test day 5. The test data also indicates that Formula X (
US-A-6,090,395 ) and Formula Z (US-A-6,110,908 ) did not meet the criteria indices of the FDA as specified in the Tentative Final Monograph for a surgical scrub product.
Formulation C | Formulation X | Formulation Y | Formulation Z | |
Irritancy Scores | 3 | 47 | 0 | 147 |
Claims (8)
- An antimicrobial composition comprising:a) an alcohol selected from the group consisting of ethyl alcohol, isopropyl alcohol and n-propyl alcohol and mixtures thereof in an amount from 60 to 95 weight percent of the total composition;b) a preservative in an amount from 0.001 to 5.0 weight percent of the total composition, wherein the preservative is one or more of the compounds selected from the group consisting of parachlorometaxylenol, phenoxy ethanol, benzalkonium chloride, benzethonium chloride, chlorhexidine gluconate, chlorhexidine diactetate, hexetidine, triclosan;c) a thickening agent in an amount from 0.01 to 3 weight percent of the total composition wherein said thickening agent is hydroxypropyl methylcellulose;d) a moisturizer and/or emollient in an amount from 0.005 to 5.0 weight percent of the total composition, wherein said moisturizer and/or emollient is one or more of the compounds selected from the group consisting of mineral oil, dimethicone, glycerin, isopropyl plamitate, propylene glycol, petrolatum, and squalane;e) a cationic emulsifier in an amount from 0.01 to 3 weight percent of the total composition wherein the cationic emulsifier is selected from(i) a 25 % active solution of behenyl trimonium methosulfate in cetearyl alcohol,(ii) a concentrate consisting of cetearyl alcohol, PEG-40 castor oil, and stearalkonium chloride, and(iii) a combination of (i) and (ii);f) water in an amount from 6 to 30 weight percent.
- The composition of claim 1 wherein the preservative is a mixture of benzenethonium chloride from 0.02 to 1.0 percent by weight and benzalkonium chloride from 0.02 to 1.0 percent by weight and chlorhexidine gluconate from 0.01 to 2.0 percent by weight.
- The composition of claim 1 which additionally contains an effective amount of diazolidinyl urea and 3-iodo-propynylbutyl carbamate.
- The composition of claim 3 wherein the total amount of diazolidinyl urea and 3-iodo-propynylbutylcarbamate is from 0.05 to 0.5 percent by weight.
- The composition of claim 3 which additionally contains an effective amount; methyl paraben, propyl paraben, and propylene glycol.
- The composition of claim 5 wherein the total amount of diazolindinyl urea, methyl paraben propyl paraben, and propylene glycol is from 0.05 to 2.0 percent by weight.
- A method of disinfecting a substrate comprising the step of applying to the substrate an effective amount of the antimicrobial composition of any of claims 1 to 6.
- The method of claim 7 wherein the substrate is the hand.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/338,457 US6723689B1 (en) | 2003-01-08 | 2003-01-08 | Emollient alcohol skin disinfecting formulation |
US338457 | 2003-01-08 | ||
PCT/US2004/000288 WO2004062589A2 (en) | 2003-01-08 | 2004-01-07 | An emollient alcohol skin disinfecting formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1581052A2 EP1581052A2 (en) | 2005-10-05 |
EP1581052B1 true EP1581052B1 (en) | 2012-06-13 |
Family
ID=32069522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04700579A Expired - Lifetime EP1581052B1 (en) | 2003-01-08 | 2004-01-07 | An emollient alcohol skin disinfecting formulation |
Country Status (4)
Country | Link |
---|---|
US (2) | US6723689B1 (en) |
EP (1) | EP1581052B1 (en) |
ES (1) | ES2389440T3 (en) |
WO (1) | WO2004062589A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10159637B2 (en) | 2016-06-10 | 2018-12-25 | Clarity Cosmetics Inc. | Non-comedogenic and non-acnegenic hair and scalp care formulations and method for use |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6224579B1 (en) * | 1999-03-31 | 2001-05-01 | The Trustees Of Columbia University In The City Of New York | Triclosan and silver compound containing medical devices |
US7329412B2 (en) | 2000-12-22 | 2008-02-12 | The Trustees Of Columbia University In The City Of New York | Antimicrobial medical devices containing chlorhexidine free base and salt |
US6846846B2 (en) * | 2001-10-23 | 2005-01-25 | The Trustees Of Columbia University In The City Of New York | Gentle-acting skin disinfectants |
CA2475224C (en) * | 2002-02-07 | 2011-11-01 | The Trustees Of Columbia University In The City Of New York | Zinc salt compositions for the prevention of mucosal irritation from spermicides and microbicides |
US7563461B2 (en) * | 2002-02-07 | 2009-07-21 | The Trustees Of Columbia University In The City Of New York | Zinc salt compositions for the prevention of dermal and mucosal irritation |
US7435429B2 (en) * | 2002-02-07 | 2008-10-14 | Trustees Of Columbia University In The City Of New York | Zinc salt compositions for the prevention of dermal and mucosal irritation |
US7745425B2 (en) * | 2002-02-07 | 2010-06-29 | The Trustees Of Columbia University In The City Of New York | Non-irritating compositions containing zinc salts |
US7879365B2 (en) * | 2002-02-07 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Zinc salt compositions for the prevention of dermal and mucosal irritation |
WO2004084973A2 (en) * | 2003-03-24 | 2004-10-07 | Becton, Dickinson And Company | Invisible antimicrobial glove and hand antiseptic |
CA2532730C (en) * | 2003-07-17 | 2013-02-26 | The Trustees Of Columbia University In The City Of New York | Antimicrobial compositions containing synergistic combinations of quaternary ammonium compounds and essential oils and/or constituents thereof |
BRPI0414883A (en) * | 2003-09-29 | 2006-12-12 | Ethena Healthcare Inc | composition, composition concentrate, and disinfectant and gel-like alcoholic compositions |
US7581119B2 (en) * | 2004-07-18 | 2009-08-25 | Apple Inc. | Method and system for discovering a power source on a peripheral bus |
ZA200701244B (en) * | 2004-08-16 | 2008-07-30 | Honeywell Int Inc | Method of preventing frost formation and facilitating the removal of winter precipitation relative to a windshield and compositions for use therein |
US7268165B2 (en) * | 2004-08-20 | 2007-09-11 | Steris Inc. | Enhanced activity alcohol-based antimicrobial compositions |
DE102004062775A1 (en) | 2004-12-21 | 2006-06-29 | Stockhausen Gmbh | Alcoholic pump foam |
KR101455554B1 (en) | 2005-03-07 | 2014-10-27 | 디이비 월드와이드 헬스케어 인코포레이티드 | High alcohol content foaming compositions with silicone-based surfactants |
US20060204466A1 (en) * | 2005-03-08 | 2006-09-14 | Ecolab Inc. | Hydroalcoholic antimicrobial composition with skin health benefits |
US7112559B1 (en) * | 2005-03-14 | 2006-09-26 | Ecolab Inc. | Thickened quaternary ammonium compound sanitizer |
US7763715B2 (en) * | 2005-04-22 | 2010-07-27 | The Procter & Gamble Company | Extracting biopolymers from a biomass using ionic liquids |
EP2957174A1 (en) * | 2005-10-25 | 2015-12-23 | Dow Global Technologies Llc | Antimicrobial composition and method |
US20070148101A1 (en) * | 2005-12-28 | 2007-06-28 | Marcia Snyder | Foamable alcoholic composition |
US7759327B2 (en) * | 2006-01-06 | 2010-07-20 | The Trustees Of Columbia University In The City Of New York | Compositions containing zinc salts for coating medical articles |
US20070185216A1 (en) * | 2006-02-09 | 2007-08-09 | Marcia Snyder | Antiviral method |
US8119115B2 (en) | 2006-02-09 | 2012-02-21 | Gojo Industries, Inc. | Antiviral method |
US8450378B2 (en) * | 2006-02-09 | 2013-05-28 | Gojo Industries, Inc. | Antiviral method |
US9629361B2 (en) * | 2006-02-09 | 2017-04-25 | Gojo Industries, Inc. | Composition and method for pre-surgical skin disinfection |
US20070253909A1 (en) * | 2006-05-01 | 2007-11-01 | Medi-Flex, Inc. | Aqueous Antiseptic Solution and Compatible Cationic Dye for Staining Skin |
US20070254854A1 (en) * | 2006-05-01 | 2007-11-01 | Medi-Flex, Inc. | Aqueous Antiseptic Solution and Compatible Anionic Dye for Staining Skin |
US20080108674A1 (en) * | 2006-05-01 | 2008-05-08 | Enturia, Inc. | Cationic antiseptic and dye formulation |
US8026407B2 (en) * | 2006-08-01 | 2011-09-27 | 3M Innovative Properties Company | Antimicrobial compression bandage |
CA2560138A1 (en) * | 2006-09-19 | 2008-03-19 | Professional Artists International Inc. | Methods for disinfectant and sanitizing cosmetics |
GB0618657D0 (en) * | 2006-09-21 | 2006-11-01 | Mainsani As | Compositions |
WO2008067028A2 (en) * | 2006-10-02 | 2008-06-05 | Dow Global Technologies Inc. | High alcohol-content foams |
US8338491B2 (en) | 2006-10-27 | 2012-12-25 | 3M Innovative Properties Company | Antimicrobial compositions |
US9981069B2 (en) | 2007-06-20 | 2018-05-29 | The Trustees Of Columbia University In The City Of New York | Bio-film resistant surfaces |
US20090082472A1 (en) * | 2007-09-25 | 2009-03-26 | Peters Marlin W | Hand sanitizer and method of preparation |
EP2625957A1 (en) * | 2007-12-31 | 2013-08-14 | 3M Innovative Properties Company | Antimicrobial compositions |
US9381150B2 (en) * | 2008-03-07 | 2016-07-05 | Kimberly-Clark Worldwide, Inc. | Alcohol antimicrobial skin sanitizing compositions including cationic compatible thickeners |
US7842725B2 (en) | 2008-07-24 | 2010-11-30 | Ecolab USA, Inc. | Foaming alcohol compositions with selected dimethicone surfactants |
US9295251B1 (en) | 2011-04-08 | 2016-03-29 | Safehands Solutions, LLC | Synergistic antimicrobial compositions of PCMX and carboxylic acid and related methods |
WO2013065051A1 (en) | 2011-11-01 | 2013-05-10 | Naveh Pharma (1996) Ltd. | Formulation and device for treating ceruminosis |
US9439841B2 (en) | 2013-06-06 | 2016-09-13 | Ecolab Usa Inc. | Alcohol based sanitizer with improved dermal compatibility and feel |
US9497962B1 (en) * | 2013-12-24 | 2016-11-22 | S.Ltech Llc | Hydroalcoholic foaming sanitizer |
DE102014115080A1 (en) * | 2014-10-16 | 2016-04-21 | Schülke & Mayr GmbH | Use of fatty acid esters to improve the antimicrobial effectiveness of an alcoholic disinfectant |
WO2017184614A1 (en) | 2016-04-20 | 2017-10-26 | S.C. Johnson & Son, Inc. | Foaming antimicrobial compositions |
US9714204B1 (en) | 2016-07-28 | 2017-07-25 | Chevron Phillips Chemical Company Lp | Process for purifying ethylene produced from a methanol-to-olefins facility |
EP3606343A1 (en) | 2017-04-04 | 2020-02-12 | Gojo Industries Inc | Methods and compounds for increasing virucidal efficacy in hydroalcoholic systems |
US11369549B2 (en) | 2017-10-12 | 2022-06-28 | Medline Industries, Lp | Antiseptic wipes |
GB2597440A (en) * | 2020-06-17 | 2022-02-02 | Creightons Plc | Skincare formulation |
CN112998012A (en) * | 2021-03-04 | 2021-06-22 | 杭州新福华无纺布有限公司 | Disinfection wet tissue |
CN113288860A (en) * | 2021-03-11 | 2021-08-24 | 江西车仆实业有限公司 | Convenient and easy-to-produce hand-washing-free disinfection gel and preparation method thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1299098C (en) * | 1985-10-28 | 1992-04-21 | John H. White | Alcohol-based antimicrobial compositions |
CA2151774C (en) * | 1994-06-27 | 1999-04-06 | Minh Quang Hoang | Skin disinfecting formulations |
ZA962455B (en) * | 1995-03-31 | 1996-10-02 | B Eugene Guthery | Fast acting and persistent topical antiseptic |
US20020022660A1 (en) * | 1998-01-20 | 2002-02-21 | Hanuman B. Jampani | Deep penetrating antimicrobial compositions |
US6107261A (en) * | 1999-06-23 | 2000-08-22 | The Dial Corporation | Compositions containing a high percent saturation concentration of antibacterial agent |
CN1138427C (en) * | 2001-05-30 | 2004-02-11 | 华为技术有限公司 | Phonetic channel exchange method for calling adaptation in mobile communication system |
-
2003
- 2003-01-08 US US10/338,457 patent/US6723689B1/en not_active Expired - Lifetime
-
2004
- 2004-01-07 US US10/595,236 patent/US20070087744A1/en not_active Abandoned
- 2004-01-07 WO PCT/US2004/000288 patent/WO2004062589A2/en active Application Filing
- 2004-01-07 ES ES04700579T patent/ES2389440T3/en not_active Expired - Lifetime
- 2004-01-07 EP EP04700579A patent/EP1581052B1/en not_active Expired - Lifetime
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10159637B2 (en) | 2016-06-10 | 2018-12-25 | Clarity Cosmetics Inc. | Non-comedogenic and non-acnegenic hair and scalp care formulations and method for use |
US10813872B2 (en) | 2016-06-10 | 2020-10-27 | Clarity Cosmetics Inc. | Hair and scalp formulations |
US11160746B2 (en) | 2016-06-10 | 2021-11-02 | Clarity Cosmetics Inc. | Non-comedogenic and non-acnegenic hair and scalp care formulations and method for use |
Also Published As
Publication number | Publication date |
---|---|
ES2389440T3 (en) | 2012-10-26 |
US6723689B1 (en) | 2004-04-20 |
US20070087744A1 (en) | 2007-04-19 |
EP1581052A2 (en) | 2005-10-05 |
WO2004062589A3 (en) | 2004-09-30 |
WO2004062589A2 (en) | 2004-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1581052B1 (en) | An emollient alcohol skin disinfecting formulation | |
US5716611A (en) | Emollient antimicrobial formulations containing povidone iodine | |
JP5068408B2 (en) | Deep penetration antimicrobial composition | |
US5512199A (en) | Hand wipe solution | |
US6517854B2 (en) | Antimicrobial sanitizing lotion with skin protection properties | |
US5629006A (en) | Skin disinfecting formulations | |
US6617294B2 (en) | Waterless sanitizing hand cleanser | |
US7488757B2 (en) | Invisible antimicrobial glove and hand antiseptic | |
JP5318351B2 (en) | Compositions and methods for preoperative skin disinfection | |
EP0937394B1 (en) | Antimicrobial composition | |
AU9822498A (en) | High glycerin containing anti-microbial cleaners | |
EP0742006A1 (en) | Non-aqueous emollient iodophor formulations | |
US20170105417A1 (en) | Skin disinfectant composition and methods for using | |
EP2787825B1 (en) | Antimicrobial composition | |
US20110207832A1 (en) | Skin disinfectant composition and methods for manufacturing and using | |
JP2020525494A (en) | Antibacterial mixture containing 4-(3-ethoxy-4-hydroxyphenyl)butan-2-one and aromatic alcohol, and cosmetic composition containing the same | |
EP2787819B1 (en) | Microbicidal composition | |
EP2787824B1 (en) | Microbicidal composition | |
AU2004253341B2 (en) | Barrier formulation comprising a silicone based emulsion | |
EP2787822B1 (en) | Microbicidal composition | |
Siquet et al. | Antibacterial agents and preservatives | |
AU2007237333B2 (en) | A wide spectrum disinfectant | |
KR20040098400A (en) | Healthcare hand,skinwashing compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050701 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
RBV | Designated contracting states (corrected) |
Designated state(s): DE ES FR GB IT |
|
17Q | First examination report despatched |
Effective date: 20061229 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: HUNT, DONALD EDWARD Inventor name: HOANG, MINH QUANG |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61Q 17/00 20060101ALI20111130BHEP Ipc: A61K 8/41 20060101ALI20111130BHEP Ipc: A61K 8/43 20060101ALI20111130BHEP Ipc: A61K 8/73 20060101ALI20111130BHEP Ipc: A61Q 19/00 20060101ALI20111130BHEP Ipc: A01N 31/02 20060101AFI20111130BHEP Ipc: A61K 8/34 20060101ALI20111130BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): DE ES FR GB IT |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602004038176 Country of ref document: DE Effective date: 20120809 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2389440 Country of ref document: ES Kind code of ref document: T3 Effective date: 20121026 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20130314 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602004038176 Country of ref document: DE Effective date: 20130314 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 13 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20221221 Year of fee payment: 20 Ref country code: FR Payment date: 20221220 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20230201 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20230103 Year of fee payment: 20 Ref country code: DE Payment date: 20221220 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 602004038176 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20240126 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20240106 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20240108 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20240108 Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20240106 |